Nyvigan

Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region.

75% of women are affected at least once during their lifetime es. 90% of those affected are considered uncomplicated and Candida (fungus) is the cause.

Resistance to Candida treatment is a major and growing problem, a sharp increase has been seen in recent decades.

Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida.

In vitro and in vivo studies show that nystatin has a good effect and there has been no development of resistance in Candida strains.

In addition Nyvigan offers:

Can be used during any stage of pregnancy and breast-feeding
No systemic exposure
No known drug interactions

Medical Information

Nyvigan (nystatin), Vaginal tablets and ointment, OTC

ATC code
G01AA01

Indication area
Nyvigan is indicated for the treatment of vulvovaginal candidiasis in adults. Please ensure compliance with official guidelines on correct use of antimycotics.

Company
Dr Pfleger Arzneimittel GmBH (Product website)

Last SPC review
2022-10-13

During concomitant use of the ointment component of Nyvigan and condoms or diaphragms, the excipient paraffin can reduce the tear resistance and thereby impair the reliability of these products. If hypersensitivity should occur, then use of the medicine should be discontinued and a suitable treatment should be carried out.

Please carefully study the information contained in the leaflet or, as applicable, on the outer packaging. Please consult a physician before usage.

Please refer to www.fass.se for more information regarding price, more specific warnings etc.